文献速递血脂与心血管预防

医护人员心血管预防:2025年ESC大会心血管健康检查

Cardiovascular Prevention among Healthcare Professionals: the ESC Congress Cardiovascular Health Check 2025.
PubMed 文献 · Eur Heart J · 2026-08-30

该研究评估了参加2025年ESC大会的1366名医护人员的心血管风险谱、知晓率、治疗使用、目标达成及亚临床动脉粥样硬化情况,并与年龄性别匹配的普通人群对照。结果显示医护人员在心血管预防中存在重要差距,尤其是指南推荐疗法的使用不足。

要点

  • 医护人员中超重最常见(46.8%),高血压(23.2%)和高脂血症(22.7%)次之。
  • 无明确ASCVD的医护人员中,亚临床动脉粥样硬化检出率达21.8%。
  • 一级预防中医护人员降压药(27.6% vs 46.5%)和降糖药(60.0% vs 85.0%)使用率低于匹配对照。

核心结论

  • 医护人员在心血管预防中存在重要差距,特别是在指南推荐疗法的使用方面。

研究设计与样本

  • 研究纳入参加2025年ESC大会心血管健康检查的医护人员1366名,进行标准化风险评估、用药及治疗目标评估,亚组行颈动脉超声。
  • 将无明确ASCVD的医护人员与REACT倡议中年龄性别匹配的普通人群(n=2732)进行比较。

主要发现

  • 医护人员中超重最常见(46.8%),高血压23.2%,高脂血症22.7%,明确ASCVD占11.1%,无ASCVD者中亚临床动脉粥样硬化占21.8%。
  • 与匹配对照相比,未识别的高脂血症(7.5% vs 8.4%;P=0.293)、高血压(11.9% vs 13.9%;P=0.079)和糖尿病(0.4% vs 0.4%;P=0.864)频率相似,仅高脂血症知晓率更高(62.2% vs 54.9%;P=0.049)。
  • 一级预防中,医护人员降压药使用率更低(27.6% vs 46.5%;P<0.001),降糖药使用率更低(60.0% vs 85.0%;P=0.001),但LDL-C达标率更高(57.5% vs 32.0%;P<0.001),收缩压达标率更高(47.5% vs 24.6%;P=0.003)。
  • 二级预防中,41.4%的医护人员使用降脂治疗,仅9.2%使用抗血小板治疗,使用降脂治疗者中仅22.2%达到LDL-C目标。

临床怎么用

  • 应关注医护人员自身的心血管风险因素管理和指南推荐疗法的使用,尤其是在一级和二级预防中。
  • 需系统性实施策略以缩小医护人员在心血管预防中的治疗差距。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Healthcare professionals (HCPs) play a central role in preventive care, yet their own cardiovascular health management remains poorly characterised. We evaluated cardiovascular risk profiles, awareness, treatment use, target achievement and subclinical atherosclerosis among HCPs attending the European Society of Cardiology (ESC) Congress. METHODS: HCPs participating in the ESC Congress Cardiovascular Health Check 2025 (n=1366) underwent standardised assessment of cardiovascular risk factors, medication use, treatment targets, and carotid ultrasonography in a subgroup. HCPs without established atherosclerotic cardiovascular disease (ASCVD) were compared with age- and sex-matched individuals from the general population (REACT initiative; n=2732). RESULTS: Among HCPs, excess body weight was the most prevalent modifiable risk factor (46.8%), followed by hypertension (23.2%), and hyperlipidaemia (22.7%). Established ASCVD was present in 11.1% and subclinical atherosclerosis was detected in 21.8% of HCPs without established ASCVD. Compared with matched controls, unrecognised hyperlipidaemia (7.5% vs. 8.4%; P=0.293), hypertension (11.9% vs. 13.9%; P=0.079), and diabetes (0.4% vs. 0.4%; P=0.864) were similarly frequent; awareness was higher only for hyperlipidaemia (62.2% vs. 54.9%; P=0.049). In primary prevention, HCPs were less likely to use recommended antihypertensive (27.6% vs. 46.5%; P<0.001) and glucose-lowering therapy (60.0% vs. 85.0%; P=0.001), but more often achieved LDL-C (57.5% vs. 32.0%; P<0.001) and systolic blood pressure targets (47.5% vs. 24.6%; P=0.003). In secondary prevention, 41.4% of HCPs used lipid-lowering therapy, only 9.2% used antiplatelet therapy, and only 22.2% of those using lipid-lowering therapy achieved the LDL-C target. CONCLUSIONS: HCPs showed important gaps in cardiovascular prevention, particularly regarding the use of guideline-recommended therapy, highlighting the need for systematic implementation strategies among HCPs.Clinical Trial Registration: NCT07613229.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Wenzl FA, Wang Y, Mass V, et al. Cardiovascular Prevention among Healthcare Professionals: the ESC Congress Cardiovascular Health Check 2025. Eur Heart J. 2026. PMID: 42669131. doi:10.1093/eurheartj/ehag736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。